Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
With
Wyeth is now a wholly owned subsidiary of Pfizer
The study will enroll approximately 375 patients with mild to moderate Alzheimer's disease at investigational sites in the United States and Europe. Patients will receive either AN-1792 or placebo, and they will be evaluated using standard clinical assessments of cognition and memory as well as experimental surrogate markers of Alzheimer's disease pathology. The goal of the study is to evaluate the clinical impact of eliciting an immune response (formation of antibodies) to the A-beta peptide in patients with Alzheimer's disease.
Age
50–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Mild to moderate Alzheimer's disease. Ability to cooperate with MRI scanning and neuropsychological testing. Live at home or in the community and a caregiver capable of accompanying the patient on all clinic visits and visiting the patient at least 5 times per week.
Clareo Health | Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease
